Showing 20 of 136 recruiting trials for “plasmablastic-lymphoma”
RecruitingNCT05809284 ↗
Determining the Mechanisms of Loss of CAR T Cell Persistence
👨⚕️ Persis Amrolia, BSc,MBBS,PhD, UCL Institute of Child Health📍 3 sites📅 Started Oct 2023View details ↗
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
👨⚕️ Nicola Goekbuget, MD, Department of Medicine, Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany📍 85 sites📅 Started Jul 2023View details ↗
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
RecruitingNCT06334835 ↗
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
👨⚕️ Ryan D. Cassaday, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Mar 2023View details ↗
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
👨⚕️ Nelson Hamerschlak, MD, PhH, Hospital Israelita Albert Einstein📍 1 site📅 Started Feb 2023View details ↗
Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL
Co-administration of CART22-65s and huCART19 for B-ALL
Pilot Imaging Study of Leukemia
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
👨⚕️ Janine Stutterheim, Dr, Princess Maxima Center for Pediatric Oncology in The Netherlands📍 112 sites📅 Started Dec 2022View details ↗
RecruitingNCT05929976 ↗
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
CAV Regimen for R/R Ph- B-ALL
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
Enrolling by InvitationNCT05509855 ↗
A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →